Soligenix Advances Psoriasis Treatment SGX302 with Promising Early Clinical Results
TL;DR
Soligenix's SGX302 offers investors exposure to a $67 billion psoriasis market opportunity with promising phase 2a clinical trial results.
Soligenix is conducting a phase 2a clinical trial of SGX302, a synthetic hypericin therapy that shows safety and biological activity for psoriasis treatment.
Soligenix's psoriasis treatment development could provide millions of patients with a novel, well-tolerated therapy for this chronic autoimmune skin condition.
Soligenix leverages synthetic hypericin technology originally developed for cancer treatment to address psoriasis in a novel photodynamic therapy approach.
Found this article helpful?
Share it with your network and spread the knowledge!
Soligenix Inc. (NASDAQ: SNGX) is advancing its phase 2a clinical trial of SGX302, a synthetic hypericin therapy targeting mild-to-moderate psoriasis, following promising phase 1/2 data that demonstrated encouraging safety and biological activity. The development represents a significant step toward addressing a chronic autoimmune skin condition affecting millions worldwide, with the global psoriasis treatment market projected to reach $67 billion by 2030.
The early trial results position SGX302 as a potential novel, well-tolerated treatment option that could expand therapeutic choices for psoriasis patients. Soligenix is leveraging its experience with hypericin-based therapies, building on the company's work with HyBryte™ (SGX301) for cutaneous T-cell lymphoma. The successful progression of SGX302 could pave the way for larger clinical studies, regulatory guidance, and eventual commercialization in the substantial dermatology market.
As a late-stage biopharmaceutical company, Soligenix focuses on developing products for rare diseases with unmet medical needs through its Specialized BioTherapeutics business segment. The company's broader development pipeline includes first-in-class innate defense regulator technology with dusquetide (SGX942) for inflammatory diseases including oral mucositis in head and neck cancer, and SGX945 for Behçet's disease. Additional information about the company's development programs is available at https://www.Soligenix.com.
The company's Public Health Solutions business segment, supported by government grants and contracts from agencies including NIAID, DTRA, and BARDA, focuses on vaccine development programs including RiVax® for ricin toxin, filovirus vaccines targeting Marburg and Ebola, and CiVax™ for COVID-19 prevention. These programs incorporate Soligenix's proprietary ThermoVax® heat stabilization platform technology.
Investors can access the latest updates and news relating to SNGX through the company's newsroom at https://ibn.fm/SNGX. The ongoing development of SGX302 represents not only a potential breakthrough in psoriasis treatment but also demonstrates Soligenix's strategic expansion within the dermatology therapeutic area, addressing a significant global health need while targeting substantial market opportunities.
Curated from InvestorBrandNetwork (IBN)
